Work

Supplementary Figure S1 from A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer

Year: 2023

Type: supplementary-materials

Abstract: Surgical specimens after neoadjuvant therapy from patients who did not respond to treatment. Color scheme: Yellow: CD8, Red: IgG4, White: CK7, Green: PD-L1, Magenta: PD-1, Blue: DAPI. Staining demonstrates minor CD8 T-cell infiltration within viable tumor tissue, with no detectable PD-1, PD-L1, or IgG4 signal present.

DOI: 10.1158/2767-9764.24018721.v1

Authors: Vina P. Nguyen, Katie M. Campbell, Theodore S. Nowicki, Nila Elumalai, Egmidio Medina, Ignacio Baselga-Carretero, Maggie L. DiNome, Helena R. Chang, Denise K. Oseguera, Antoni Ribas, John A. Glaspy

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4386091362

Cites:

Cited by:

Related to: 10